Abstract | BACKGROUND: The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. OBJECTIVE: DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: 33 community, university, or university-affiliated hospitals. PATIENTS: 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. INTERVENTION: Daily subcutaneous ardeparin (100 anti-Xa IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. MEASUREMENTS: Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. RESULTS: Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% CI, 0.3 to 1.7]; P > 0.2; absolute difference, -0.56 percentage points [CI, -2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). CONCLUSIONS: Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2-percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for most patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.
|
Authors | J A Heit, C G Elliott, A A Trowbridge, B F Morrey, M Gent, J Hirsh |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 132
Issue 11
Pg. 853-61
(Jun 06 2000)
ISSN: 0003-4819 [Print] United States |
PMID | 10836911
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Heparin, Low-Molecular-Weight
- Placebos
- ardeparin
|
Topics |
- Adult
- Aged
- Ambulatory Care
- Arthroplasty, Replacement, Hip
(adverse effects)
- Arthroplasty, Replacement, Knee
(adverse effects)
- Cause of Death
- Double-Blind Method
- Drug Administration Schedule
- Female
- Hemorrhage
(chemically induced)
- Heparin, Low-Molecular-Weight
(administration & dosage, adverse effects)
- Humans
- Male
- Middle Aged
- Placebos
- Pulmonary Embolism
(etiology, prevention & control)
- Thrombocytopenia
(chemically induced)
- Thromboembolism
(etiology, prevention & control)
- Venous Thrombosis
(etiology, prevention & control)
|